CN110612109A - 使用BCL-2抑制剂连同α-发射放射免疫治疗来治疗癌症的方法 - Google Patents

使用BCL-2抑制剂连同α-发射放射免疫治疗来治疗癌症的方法 Download PDF

Info

Publication number
CN110612109A
CN110612109A CN201880027661.XA CN201880027661A CN110612109A CN 110612109 A CN110612109 A CN 110612109A CN 201880027661 A CN201880027661 A CN 201880027661A CN 110612109 A CN110612109 A CN 110612109A
Authority
CN
China
Prior art keywords
bcl
labeled
venetoclax
hum195
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880027661.XA
Other languages
English (en)
Chinese (zh)
Inventor
德拉甘·契契奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinide Pharmaceutical Co Ltd
Original Assignee
Actinide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actinide Pharmaceutical Co Ltd filed Critical Actinide Pharmaceutical Co Ltd
Publication of CN110612109A publication Critical patent/CN110612109A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201880027661.XA 2017-04-28 2018-04-26 使用BCL-2抑制剂连同α-发射放射免疫治疗来治疗癌症的方法 Pending CN110612109A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491803P 2017-04-28 2017-04-28
US62/491,803 2017-04-28
PCT/US2018/029607 WO2018200841A1 (en) 2017-04-28 2018-04-26 Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic

Publications (1)

Publication Number Publication Date
CN110612109A true CN110612109A (zh) 2019-12-24

Family

ID=63919290

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880027661.XA Pending CN110612109A (zh) 2017-04-28 2018-04-26 使用BCL-2抑制剂连同α-发射放射免疫治疗来治疗癌症的方法

Country Status (8)

Country Link
US (4) US11364235B2 (enExample)
EP (1) EP3615047A4 (enExample)
JP (3) JP2020517704A (enExample)
CN (1) CN110612109A (enExample)
BR (1) BR112019022308A2 (enExample)
CA (1) CA3059752A1 (enExample)
MX (1) MX2019012660A (enExample)
WO (1) WO2018200841A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115209925A (zh) * 2020-01-10 2022-10-18 融合制药公司 持续性免疫疗法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615047A4 (en) * 2017-04-28 2021-01-13 Actinium Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER WITH A BCL-2 INHIBITOR ASSOCIATED WITH ALPHA-EMISSING RADIOIMMUNOTHERAPY
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
JP2022516170A (ja) * 2019-01-04 2022-02-24 アクティニウム ファーマシューティカルズ インコーポレイテッド Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法
WO2022055842A1 (en) * 2020-09-08 2022-03-17 Actinium Pharmaceuticals, Inc. Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058007A1 (en) * 2000-09-15 2002-05-16 David Scheinberg Targeted alpha particle therapy using actinium-225 conjugates
US20120004311A1 (en) * 2009-04-15 2012-01-05 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic b-cell lymphoma/leukemia-2 (bcl-2)
WO2016014576A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US20160113925A1 (en) * 2014-10-22 2016-04-28 Emory University Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
US20160220573A1 (en) * 2015-02-03 2016-08-04 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2017021963A1 (en) * 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
PT3280729T (pt) * 2015-04-08 2022-08-01 Novartis Ag Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19
EP3615047A4 (en) * 2017-04-28 2021-01-13 Actinium Pharmaceuticals, Inc. METHOD OF TREATMENT OF CANCER WITH A BCL-2 INHIBITOR ASSOCIATED WITH ALPHA-EMISSING RADIOIMMUNOTHERAPY

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058007A1 (en) * 2000-09-15 2002-05-16 David Scheinberg Targeted alpha particle therapy using actinium-225 conjugates
US20120004311A1 (en) * 2009-04-15 2012-01-05 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic b-cell lymphoma/leukemia-2 (bcl-2)
WO2016014576A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US20160113925A1 (en) * 2014-10-22 2016-04-28 Emory University Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors
US20160220573A1 (en) * 2015-02-03 2016-08-04 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2017021963A1 (en) * 2015-08-03 2017-02-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APOSTOLIA-MARIA TSIMBERIDOU等: "《Targeted Therapy in Translational Cancer Research》", WILEY *
JOSEPH G. JURCIC等: "Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML)", 《BLOOD》, vol. 128, no. 22, 2 December 2016 (2016-12-02) *
SHYRIL O"STEEN等: "Venetoclax Synergizes with Radiation Therapy for Treatment of B-Cell Lymphomas", 《BLOOD》 *
SHYRIL O"STEEN等: "Venetoclax Synergizes with Radiation Therapy for Treatment of B-Cell Lymphomas", 《BLOOD》, vol. 128, no. 22, 2 December 2016 (2016-12-02), XP055755310 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115209925A (zh) * 2020-01-10 2022-10-18 融合制药公司 持续性免疫疗法

Also Published As

Publication number Publication date
EP3615047A4 (en) 2021-01-13
JP2020517704A (ja) 2020-06-18
US20250017919A1 (en) 2025-01-16
WO2018200841A1 (en) 2018-11-01
US12133849B2 (en) 2024-11-05
MX2019012660A (es) 2020-07-27
US20200383974A1 (en) 2020-12-10
US11844799B2 (en) 2023-12-19
US20220273648A1 (en) 2022-09-01
EP3615047A1 (en) 2020-03-04
JP2020158544A (ja) 2020-10-01
JP2023165952A (ja) 2023-11-17
US11364235B2 (en) 2022-06-21
CA3059752A1 (en) 2018-11-01
US20240131025A1 (en) 2024-04-25
US20240226095A9 (en) 2024-07-11
BR112019022308A2 (pt) 2020-05-26

Similar Documents

Publication Publication Date Title
US12133849B2 (en) Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic
JP7274646B2 (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
US20220072167A1 (en) Methods for Treating Cancer Using Combinations of PARP Inhibitors and Antibody Radioconjugates
JP2023546679A (ja) がん治療における放射免疫療法とｃｄ４７遮断の併用
KR20200010472A (ko) 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임
US20230092668A1 (en) Radioconjugates targeting cd33 in the treatment of cancers
US20230302167A1 (en) Radioconjugates targeting cd33 in the treatment of cancers
US20230302168A1 (en) Dr5 radioimmunotherapy in the treatment of solid cancers
WO2023009189A1 (en) Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
HK40018488A (en) Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
JP2016527200A (ja) Ｃｄ３７抗体とクロラムブシルの併用
CN103041387B (zh) 恶性b细胞淋巴瘤抗体药物的新用途
US20240299600A1 (en) Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac225
EP3706785B1 (en) Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies
Carswell et al. 90Y ibritumomab tiuxetan

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40018488

Country of ref document: HK